文献速递银屑病与炎症性皮肤病

抑制IL-23或IL-17A可预防银屑病相关血栓形成

Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A.
PubMed 文献 · J Invest Dermatol · 2017-09-23

研究在KC-Tie2银屑病样小鼠模型中,系统给予靶向IL-17A、IL-17RA、IL-12/23p40或IL-23p19的抗体治疗6周,评估皮肤炎症、血栓形成时间及脾脏免疫细胞比例。结果显示各抗体均显著改善皮肤炎症,延长闭塞性血栓形成时间,且与棘层肥厚减轻相关;脾脏中性粒细胞减少而单核细胞和CD4 T细胞未变。提示靶向抑制IL-23或IL-17A可同时改善银屑病样皮肤病和心血管结局。

要点

  • 靶向IL-23或IL-17A治疗改善银屑病样小鼠皮肤炎症并延长血栓形成时间。
  • 血栓形成时间延长与棘层肥厚减轻相关。
  • 皮肤炎症改善伴随脾脏中性粒细胞减少,单核细胞和CD4 T细胞未变。

核心结论

  • 靶向抑制IL-23或IL-17A可改善小鼠银屑病样皮肤病并改善心血管疾病。

研究设计与样本

  • KC-Tie2银屑病小鼠系统给予靶向IL-17A、IL-17RA、IL-12/23p40或IL-23p19的抗体治疗6周。
  • 检测皮肤炎症、血栓形成凝血时间及脾脏单核细胞、中性粒细胞和CD4 T细胞百分比。

主要发现

  • 靶向IL-23、IL-17A或IL-17RA的抗体均显著改善KC-Tie2小鼠皮肤炎症。
  • 这些小鼠闭塞性血栓形成时间延长,并与棘层肥厚减轻相关。
  • 皮肤炎症减轻平行于脾脏中性粒细胞(CD11b+Ly6G+)减少,但单核细胞(CD11b+Ly6Chigh)或T细胞(CD4+)未减少。

临床怎么用

  • 提示靶向IL-23或IL-17A的生物制剂在治疗银屑病皮肤炎症的同时可能改善心血管结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis patients experience chronic systemic skin inflammation and develop cardiovascular comorbidities that shorten their lifespan. Whether cardiovascular disease is improved by treatment with current biologics that target disease-specific pathways is unclear. KC-Tie2 mice develop psoriasiform skin inflammation with increases in IL-23 and IL-17A and proinflammatory monocytosis and neutrophilia that precedes development of carotid artery thrombus formation. To examine whether targeted blockade of IL-23 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically for 6 weeks with antibodies targeting IL-17A, IL-17RA, IL-12/23p40, or IL-23p19. Skin inflammation; thrombosis clotting times; and percentage of splenic monocytes, neutrophils, and CD4 T cells were examined. Skin inflammation significantly improved in KC-Tie2 mice treated with each of the antibodies targeting IL-23, IL-17A, or IL-17RA, consistent with clinical efficacy observed in psoriasis patients. The time to occlusive thrombus formation lengthened in these mice and correlated with attenuated acanthosis. This decrease in skin inflammation paralleled decreases in splenic neutrophils (CD11b+Ly6G+) but not monocytes (CD11b+Ly6Chigh) or T cells (CD4+). Our data show that targeted inhibition of IL-23 or IL-17A improves psoriasis-like skin disease and also improves cardiovascular disease in mice.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Li Y, Golden JB, Camhi MI, et al. Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A. J Invest Dermatol. 2017. PMID: 28951241. doi:10.1016/j.jid.2017.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。